Health

FDA approves Gilead's remdesivir as coronavirus treatment


A lab technicians shows the coronavirus disease (COVID-19) treatment drug “Remdesivir”.

Amr Abdallah Dalsh | Reuters

The Food and Drug Administration on Thursday approved Gilead Sciences‘ antiviral drug remdesivir as a treatment for the coronavirus.

In May, the FDA granted the drug an emergency use authorization, allowing hospitals and doctors to use the drug on patients hospitalized with the disease even though the drug has not been formally approved by the agency. The intravenous drug has helped shorten the recovery time of some hospitalized Covid-19 patients. It was one of the drugs used to treat President Donald Trump, who tested positive for the virus earlier this month.

The drug will be used for Covid-19 patients requiring hospitalization, Gilead said. Remdesivir is now the first and only fully approved treatment in the U.S. for Covid-19, which has infected more than 41.3 million and killed more than 1 million, according to data compiled by Johns Hopkins University.

“Since the beginning of the COVID-19 pandemic, Gilead has worked relentlessly to help find solutions to this global health crisis,” Gilead CEO Daniel O’Day said in a statement. “It is incredible to be in the position today, less than one year since the earliest case reports of the disease now known as COVID-19, of having an FDA-approved treatment in the U.S. that is available for all appropriate patients in need.”

In August, the company said it planned to produce more than 2 million treatment courses of the drug by the end of the year and anticipated being able to make “several million more” in 2021, adding it has increased supply of the drug more than fiftyfold since January. Its manufacturing network now includes more than 40 companies in North America, Europe and Asia.

This is breaking news. Please check back for updates.



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.